- Home
- PFD vs CRDF Comparison
PFD vs CRDF Comparison
Compare PFD & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PFD
- CRDF
- Stock Information
- Founded
- PFD 1990
- CRDF 1999
- Country
- PFD United States
- CRDF United States
- Employees
- PFD N/A
- CRDF N/A
- Industry
- PFD Investment Managers
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PFD Finance
- CRDF Health Care
- Exchange
- PFD Nasdaq
- CRDF Nasdaq
- Market Cap
- PFD 143.2M
- CRDF 144.4M
- IPO Year
- PFD N/A
- CRDF N/A
- Fundamental
- Price
- PFD $11.69
- CRDF $2.20
- Analyst Decision
- PFD
- CRDF Strong Buy
- Analyst Count
- PFD 0
- CRDF 5
- Target Price
- PFD N/A
- CRDF $11.10
- AVG Volume (30 Days)
- PFD 33.2K
- CRDF 1.2M
- Earning Date
- PFD 01-01-0001
- CRDF 11-06-2025
- Dividend Yield
- PFD 6.30%
- CRDF N/A
- EPS Growth
- PFD N/A
- CRDF N/A
- EPS
- PFD N/A
- CRDF N/A
- Revenue
- PFD N/A
- CRDF $545,000.00
- Revenue This Year
- PFD N/A
- CRDF N/A
- Revenue Next Year
- PFD N/A
- CRDF N/A
- P/E Ratio
- PFD N/A
- CRDF N/A
- Revenue Growth
- PFD N/A
- CRDF N/A
- 52 Week Low
- PFD $8.53
- CRDF $1.90
- 52 Week High
- PFD $11.18
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- PFD 80.08
- CRDF 39.69
- Support Level
- PFD $11.44
- CRDF $1.90
- Resistance Level
- PFD $11.49
- CRDF $2.39
- Average True Range (ATR)
- PFD 0.05
- CRDF 0.13
- MACD
- PFD 0.02
- CRDF 0.04
- Stochastic Oscillator
- PFD 94.53
- CRDF 54.63
About PFD Flaherty & Crumrine Preferred and Income Fund Incorporated
Flaherty & Crumrine Prefd Inc Fund Inc is a United States-based diversified, closed-end management investment company. Its investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. The fund invests in a diversified portfolio of preferred securities, which includes traditional preferred stocks eligible for the inter-corporate dividends received a deduction and fully taxable preferred securities.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.